Drug Profile
Research programme: respiratory syncytial virus vaccine - LigoCyte Pharmaceuticals
Alternative Names: Respiratory syncytial virus virus-like particle vaccine - LigoCyte; RSV VLP vaccine - LigoCyteLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator LigoCyte Pharmaceuticals
- Developer Takeda
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in USA (Parenteral)
- 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda
- 06 Jul 2011 Preclinical trials in Respiratory syncytial virus infections in USA (Parenteral)